Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Christina, Lindahl"'
Publikováno v:
PLoS ONE, Vol 12, Iss 6, p e0178423 (2017)
We investigated how memory for faces and voices (presented separately and in combination) varies as a function of sex and emotional expression (anger, disgust, fear, happiness, sadness, and neutral). At encoding, participants judged the expressed emo
Externí odkaz:
https://doaj.org/article/0634f63d10ee447fb9984f421457412a
Autor:
Michael Szarek, Terje R. Pedersen, Nilo B. Cater, Anders G. Olsson, Ingar Holme, Rana Fayyad, Mogens Lytken Larsen, Christina Lindahl, Ole Faergeman, Matti J. Tikkanen, John J.P. Kastelein
Publikováno v:
Journal of the American College of Cardiology. 54:2353-2357
Objectives This post-hoc analysis of the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial was designed to assess the comparative treatment efficacy of high-dose at ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0564e67e1c2b28f7283cf32ed43744db
https://doi.org/10.1016/j.jacc.2009.08.035
https://doi.org/10.1016/j.jacc.2009.08.035
Autor:
John J.P. Kastelein, Hallvard Holdaas, Mogens Lytken Larsen, Anders G. Olsson, Rana Fayyad, Ole Faergeman, Ingar Holme, Christina Lindahl, Matti J. Tikkanen, Terje R. Pedersen
Publikováno v:
Journal of Internal Medicine. 267:567-575
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: Results from the IDEAL trial. J Intern Med 2010; 267:567-575. Objectiv ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6156cfed4397a4a0879c48b8d9bad67
https://doi.org/10.1111/j.1365-2796.2009.02176.x
https://doi.org/10.1111/j.1365-2796.2009.02176.x
Autor:
Terje R. Pedersen, Timo E. Strandberg, Mogens Lytken Larsen, John J.P. Kastelein, Christina Lindahl, Matti J. Tikkanen, Anders G. Olsson, Ole Faergeman, Ingar Holme
Publikováno v:
Atherosclerosis. 205:522-527
Background Very few, if any, studies have assessed the ability of apolipoproteins to predict new-onset of congestive heart failure (HF) in statin-treated patients with coronary heart disease (CHD). Aims To employ the Incremental Decrease in End point
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8973ddf864ecde2e3739a43a1deabbc
https://doi.org/10.1016/j.atherosclerosis.2009.01.023
https://doi.org/10.1016/j.atherosclerosis.2009.01.023
Autor:
John J.P. Kastelein, Terje R. Pedersen, Anders G. Olsson, Ole Faergeman, Ingar Holme, Erik S.G. Stroes, Nicholas J. Wareham, Mogens Lytken Larsen, Matti J. Tikkanen, Wim A. van der Steeg, Christina Lindahl, Kay-Tee Khaw, S. Matthijs Boekholdt
Publikováno v:
Journal of the American College of Cardiology. 51(6):634-642
Objectives: This study was designed to assess the relationship of high-density-lipoprotein cholesterol (HDL-C), HDL particle size, and apolipoprotein A-I (apoA-I) with the occurrence of coronary ar ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb2dd7fec5ad834c9a69965be8e213b6
Autor:
Terje R. Pedersen, Gary Palmer, Ole Faergeman, John J.P. Kastelein, Mogens Lytken Larsen, Fredrik S. Bendiksen, Anders G. Olsson, Christina Lindahl, Ingar Holme, Matti J. Tikkanen
Publikováno v:
American journal of cardiology, 94(6), 720-724. Elsevier Inc.
The Incremental Decrease in End Points through Aggressive Lipid Lowering (IDEAL) study is an investigator-initiated trial designed to determine whether additional clinical benefit might be gained through a strategy that decreases levels of low-densit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57298b922e94934a730e9904df0cc869
https://doi.org/10.1016/j.amjcard.2004.06.003
https://doi.org/10.1016/j.amjcard.2004.06.003
Autor:
Terje R. Pedersen, Chuan-Chuan Wun, Phillip J. Barter, Christina Lindahl, Anders G. Olsson, Ingar Holme, Rana Fayyad, Matti J. Tikkanen, Nanette K. Wenger, John J.P. Kastelein, Ole Faergeman, Mogens Lytken Larsen, Matthijs Boekholdt
Publikováno v:
Journal of the American College of Cardiology. 59(13)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac8f2f930fabe8b0af81787b7f4d0f3d
Autor:
Terje R. Pedersen, Mogens Lytken Larsen, John J.P. Kastelein, Christina Lindahl, Ole Faergeman, Rana Fayyad, Matti J. Tikkanen, Anders G. Olsson, Ingar Holme
Publikováno v:
Olsson, A G, Lindahl, C, Holme, I, Fayyad, R, Faergeman, O, Kastelein, J J P, Tikkanen, M J, Larsen, M L, Pedersen, T R & Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group 2011, ' LDL cholesterol goals and cardiovascular risk during statin treatment : the IDEAL study ', European Journal of Cardiovascular Prevention & Rehabilitation, vol. 18, no. 2, pp. 262-9 . https://doi.org/10.1177/1741826710389391
European journal of cardiovascular prevention and rehabilitation, 18(2), 262-269. SAGE Publications Inc.
Olsson, A G, Lindahl, C, Holme, I, Fayyad, R, Faergeman, O, Kastelein, J J P, Tikkanen, M J, Larsen, M L, Pedersen, T R & Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group 2011, ' LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study ', European Journal of Cardiovascular Prevention and Rehabilitation, vol. 18, no. 2, pp. 262-9 . https://doi.org/10.1177/1741826710389391
European journal of cardiovascular prevention and rehabilitation, 18(2), 262-269. SAGE Publications Inc.
Olsson, A G, Lindahl, C, Holme, I, Fayyad, R, Faergeman, O, Kastelein, J J P, Tikkanen, M J, Larsen, M L, Pedersen, T R & Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group 2011, ' LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study ', European Journal of Cardiovascular Prevention and Rehabilitation, vol. 18, no. 2, pp. 262-9 . https://doi.org/10.1177/1741826710389391
Aims: We assessed the proportion of patients treated with either simvastatin 20 or 40 mg or atorvastatin 80 mg who achieved low-density lipoprotein cholesterol (LDL-C) goals of 2.5 or 2.0 mmol/l in the Incremental Decrease in End Points Through Aggre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::797ea1cb9a6c5fff3cc12ea51dea81d7
https://pure.au.dk/portal/da/publications/ldl-cholesterol-goals-and-cardiovascular-risk-during-statin-treatment(2aa4a8f1-9732-4b43-8e66-5a35a91b51c8).html
https://pure.au.dk/portal/da/publications/ldl-cholesterol-goals-and-cardiovascular-risk-during-statin-treatment(2aa4a8f1-9732-4b43-8e66-5a35a91b51c8).html
Autor:
Terje R. Pedersen, Matti J. Tikkanen, Mogens Lytken Larsen, John J.P. Kastelein, Anders G. Olsson, Christina Lindahl, Nilo B. Cater, Ingar Holme, Michael Szarek, Ole Faergeman
Publikováno v:
American journal of cardiology, 106(3), 354-359. Elsevier Inc.
Pedersen, TR, Cater, N B, Faergeman, O, Kastelein, J J P, Olsson, A G, Tikkanen, M J, Holme, I, Larsen, M L, Lindahl, C & Szarek, M 2010, ' Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial) ', American Journal of Cardiology, vol. 106, no. 3, pp. 354-9 . https://doi.org/10.1016/j.amjcard.2010.03.033
Pedersen, TR, Cater, N B, Faergeman, O, Kastelein, J J P, Olsson, A G, Tikkanen, M J, Holme, I, Larsen, M L, Lindahl, C & Szarek, M 2010, ' Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial) ', American Journal of Cardiology, vol. 106, no. 3, pp. 354-9 . https://doi.org/10.1016/j.amjcard.2010.03.033
Previous studies have demonstrated that benefits of intensive statin therapy compared to standard statin therapy begin shortly after an acute event and are continued up to 2 years of follow-up. However, whether efficacy and safety of intensive statin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcc2868bae242d2be67f9e6a7190072a
https://pure.amc.nl/en/publications/comparison-of-atorvastatin-80-mgday-versus-simvastatin-20-to-40-mgday-on-frequency-of-cardiovascular-events-late-five-years-after-acute-myocardial-infarction-from-the-incremental-decrease-in-end-points-through-aggressive-lipid-lowering-ideal-trial(56ca67bf-22ab-46d5-a83d-884771b84f41).html
https://pure.amc.nl/en/publications/comparison-of-atorvastatin-80-mgday-versus-simvastatin-20-to-40-mgday-on-frequency-of-cardiovascular-events-late-five-years-after-acute-myocardial-infarction-from-the-incremental-decrease-in-end-points-through-aggressive-lipid-lowering-ideal-trial(56ca67bf-22ab-46d5-a83d-884771b84f41).html
Autor:
Matti J, Tikkanen, Michael, Szarek, Rana, Fayyad, Ingar, Holme, Nilo B, Cater, Ole, Faergeman, John J P, Kastelein, Anders G, Olsson, Mogens Lytken, Larsen, Christina, Lindahl, Terje R, Pedersen
Publikováno v:
Journal of the American College of Cardiology. 54(25)
This post-hoc analysis of the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial was designed to assess the comparative treatment efficacy of high-dose atorvastatin and usual-dose simvastatin for the prevention of even
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ec43588752946bc6deebb49e2acbaa1f
https://pubmed.ncbi.nlm.nih.gov/20510223
https://pubmed.ncbi.nlm.nih.gov/20510223